Vaccines specialist Intercell AG of Vienna, Austria, completed the acquisition of Pelias AG, gaining ownership of a Pseudomonas vaccine in Phase I clinical trials.
Pelias will remain a separate legal entity, operating as a subsidiary of Intercell AG. Apart from the Pseudomonas vaccine, Pelias has other vaccines programmes targeting hospital-acquired infections in development.
Receive the Funding Newswire [full access requires a subscription] each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening.
Sign up for the Funding Newswire
Follow where the public and private R&I money is going and which collaborative opportunities you can pursue.
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.
